Page 45 - Read Online

Nwaiwu et al. Mini-invasive Surg. 2025;9:20 https://dx.doi.org/10.20517/2574-1225.2024.112 Page 19 of 20

loss and co-morbidities at six months and one year. J Visc Surg. 2023;160:S38-46. DOI PubMed
25. Singh S, Bazarbashi AN, Khan A, et al. Primary obesity surgery endoluminal (POSE) for the treatment of obesity: a systematic review
and meta-analysis. Surg Endosc. 2022;36:252-66. DOI PubMed PMC
26. Ker J, Singh SP, Bai Y, Rao J, Lim T, Wang L. Image thresholding improves 3-dimensional convolutional neural network diagnosis of
different acute brain hemorrhages on computed tomography scans. Sensors. 2019;19:2167. DOI PubMed PMC
27. Espinós JC, Turró R, Moragas G, et al. Gastrointestinal physiological changes and their relationship to weight loss following the POSE
procedure. Obes Surg. 2016;26:1081-9. DOI PubMed
28. Sullivan S, Swain JM, Woodman G, Antonetti M, De La Cruz-Muñoz N, Jonnalagadda SS, et al. Randomized sham-controlled trial
evaluating efficacy and safety of endoscopic gastric plication for primary obesity: the ESSENTIAL trial. Obesity. 2017;25:294-301.
DOI PubMed
29. Lopez-Nava G, Asokkumar R, Turró Arau R, Neto MG, Dayyeh BA. Modified primary obesity surgery endoluminal (POSE-2)
procedure for the treatment of obesity. VideoGIE. 2020;5:91-3. DOI PubMed PMC
30. Lopez Nava G, Arau RT, Asokkumar R, et al. Prospective multicenter study of the primary obesity surgery endoluminal (POSE 2.0)
procedure for treatment of obesity. Clin Gastroenterol Hepatol. 2023;21:81-9.e4. DOI PubMed
31. Jense MTF, Hodde T, Palm-Meinders IH, et al. The POSE-2 procedure for people with obesity: a safe and effective treatment option.
Obes Surg. 2024;34:3686-93. DOI PubMed PMC
32. Gys B, Plaeke P, Lamme B, et al. Endoscopic Gastric plication for morbid obesity: a systematic review and meta-analysis of published
data over time. Obes Surg. 2019;29:3021-9. DOI PubMed
33. Khan Z, Khan MA, Hajifathalian K, et al. Efficacy of endoscopic interventions for the management of obesity: a meta-analysis to
compare endoscopic sleeve gastroplasty, AspireAssist, and primary obesity surgery endolumenal. Obes Surg. 2019;29:2287-98. DOI
PubMed
34. Moreno C, Closset J, Dugardeyn S, et al. Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese
patients: results of the second human pilot study. Endoscopy. 2008;40:406-13. DOI PubMed
35. Leccesi L, Panunzi S, De Gaetano A, et al. Effects of transoral gastroplasty on glucose homeostasis in obese subjects. J Clin
Endocrinol Metab. 2013;98:1901-10. DOI PubMed
36. Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome.
Gastrointest Endosc. 2011;74:1248-58. DOI PubMed
37. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies.
Gastroenterology. 2017;152:1791-801. DOI PubMed
38. Tawadros A, Makar M, Kahaleh M, Sarkar A. Overview of bariatric and metabolic endoscopy interventions. Ther Adv Gastrointest
Endosc. 2020;13:2631774520935239. DOI PubMed PMC
39. Shenoy A, Schulman AR. Advances in endobariatrics: past, present, and future. Gastroenterol Rep. 2023;11:goad043. DOI PubMed
PMC
40. Tate CM, Geliebter A. Intragastric balloon treatment for obesity: review of recent studies. Adv Ther. 2017;34:1859-75. DOI PubMed
41. Qureshi H, Saeed N, Jovani M. Updates in endoscopic bariatric and metabolic therapies. J Clin Med. 2023;12:1126. DOI PubMed
PMC
42. Abdulla M, Mohammed N, AlQamish J. Overview on the endoscopic treatment for obesity: a review. World J Gastroenterol.
2023;29:5526-42. DOI PubMed PMC
43. Navez B, Ungureanu F, Michiels M, et al. Surgical management of acute cholecystitis: results of a 2-year prospective multicenter
survey in Belgium. Surg Endosc. 2012;26:2436-45. DOI PubMed
44. Choi SJ, Choi HS. Various intragastric balloons under clinical investigation. Clin Endosc. 2018;51:407-15. DOI PubMed PMC
45. Sachdev P, Reece L, Thomson M, et al. Intragastric balloon as an adjunct to lifestyle programme in severely obese adolescents: impact
on biomedical outcomes and skeletal health. Int J Obes. 2017;42:115-8. DOI PubMed PMC
46. FDA. Summary of safety and effectiveness data (SSED): ORBERATM intragastric balloon system. 2015. Available from: http://www.
accessdata.fda.gov/cdrh_docs/pdf10/P100034b.pdf. [Last accessed on 20 Jun 2025].
47. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee; Abu Dayyeh BK, Kumar N, Edmundowicz SA, et al.
ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting
endoscopic bariatric therapies. Gastrointest Endosc. 2015;82:425-38.e5. DOI PubMed
48. Kozłowska-Petriczko K, Pawlak KM, Wojciechowska K, et al. The efficacy comparison of endoscopic bariatric therapies: 6-month
versus 12-month intragastric balloon versus endoscopic sleeve gastroplasty. Obes Surg. 2022;33:498-505. DOI PubMed PMC
49. Suchartlikitwong S, Laoveeravat P, Mingbunjerdsuk T, et al. Usefulness of the ReShape intragastric balloon for obesity. Proc.
2019;32:192-5. DOI PubMed PMC
50. Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label,
randomised clinical trial. Lancet. 2021;398:1965-73. DOI PubMed
51. Sullivan S, Swain J, Woodman G, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon
system for weight loss. Surg Obes Relat Dis. 2018;14:1876-89. DOI PubMed
52. Ienca R, Al Jarallah M, Caballero A, et al. The procedureless elipse gastric balloon program: multicenter experience in 1770
consecutive patients. Obes Surg. 2020;30:3354-62. DOI PubMed PMC
53. Kotinda APST, de Moura DTH, Ribeiro IB, et al. Efficacy of intragastric balloons for weight loss in overweight and obese adults: a